Osterweis Capital Management’s Summit Therapeutics SMMT Stock Holding History

Osterweis Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$72.8K	Hold	5,000	–	–	﹤0.01%	174
2026 Q1	$94.8K	Hold	5,000	–	–	﹤0.01%	160
2025 Q4	$87.5K	Hold	5,000	–	–	﹤0.01%	180
2025 Q3	$103K	Hold	5,000	–	–	﹤0.01%	169
2025 Q2	$106K	Hold	5,000	–	–	0.01%	173
2025 Q1	$96.5K	Hold	5,000	–	–	﹤0.01%	141
2024 Q4	$89.2K	Hold	5,000	–	–	﹤0.01%	155
2024 Q3	$110K	Hold	5,000	–	–	0.01%	154
2024 Q2	$39K	Hold	5,000	–	–	﹤0.01%	181
2024 Q1	$20.7K	Hold	5,000	–	–	﹤0.01%	179
2023 Q4	$13.1K	Hold	5,000	–	–	﹤0.01%	183
2023 Q3	$9.35K	Hold	5,000	–	–	﹤0.01%	198
2023 Q2	$12.6K	Hold	5,000	–	–	﹤0.01%	196
2023 Q1	$8.75K	Hold	5,000	–	–	﹤0.01%	200
2022 Q4	$21.3K	Hold	5,000	–	–	﹤0.01%	201
2022 Q3	$6K	Buy	+5,000	New	+$5.66K	﹤0.01%	215

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Osterweis Capital Management's SMMT Position: Q2 2026 in Review

Osterweis Capital Management held its Summit Therapeutics (SMMT) position steady in Q2 2026 at 5,000 shares worth $72.8K. The position accounts for ﹤0.01% of the portfolio, ranked #174.

Osterweis Capital Management first reported a position in SMMT in Q3 2022 and has held it in 16 quarters since. The position peaked at $110K in Q3 2024. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Osterweis Capital Management held 5,000 shares of Summit Therapeutics worth $72.8K as of Q2 2026.
Osterweis Capital Management left its Summit Therapeutics share count unchanged in Q2 2026.
Summit Therapeutics made up ﹤0.01% of Osterweis Capital Management's portfolio in Q2 2026, its #174 holding.
Osterweis Capital Management first reported a position in Summit Therapeutics in Q3 2022 and has held it in 16 quarters since.
Osterweis Capital Management's Summit Therapeutics position peaked at $110K in Q3 2024.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Osterweis Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.